RTTNews | Feb 17, 2021 10:41AM EST

10:40 Wednesday, February 17, 2021 (RTTNews.com) - Nektar Therapeutics (NKTR) shares are rising more than 13 percent on Wednesday morning as the company entered into a clinical trial collaboration and supply agreement with Merck for a Phase 2/3 study of bempegaldesleukin Nektar's investigational IL-2 pathway agent, in combination with Merck's KEYTRUDA. The trial is intended for first-line treatment of patients with metastatic or unresectable recurrent squamous cell carcinoma of the head and neck whose tumors express PD-L1. Currently, shares are at $25.49, up 13.49 percent from the previous close of $22.46. For the 52-week period, the shares have traded in a range of $13.63-$25.95 on a volume of 1,196,426.

Read the original article on RTTNews ( https://www.rttnews.com/3170462/stock-alert-nektar-therapeutics-up-13-on-collaboration-with-merck.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved